Literature DB >> 33332036

[Mortality and re-admission after hospitalization with COVID-19].

Wouter T Leijte1, Nicolaas M M Wagemaker1, Tom D A van Kraaij2, Martijn D de Kruif1, Guy J M Mostard2, Math P G Leers3, Rémy L M Mostard1, Jacqueline Buijs1, Daan J L van Twist2,4.   

Abstract

OBJECTIVE: Hospitalization for corona virus disease 2019 (COVID-19) may be followed by complications after discharge. We aimed to evaluate mortality, readmission rate, and readmission characteristics after hospitalization with COVID-19.
DESIGN: A retrospective cohort study
METHODS: Inclusion of all patients hospitalized for COVID-19 between March 1, 2020, and June 1, 2020 in Zuyderland Medical Centre, The Netherlands. Main outcome measures were mortality and readmission after hospitalization. Univariate and multivariate regression analysis were performed to identify risk factors for death and readmission.
RESULTS: A total of 769 patients hospitalized with COVID-19 (mean age 70 ± 14 years; 39% female) were included in the study. In-hospital mortality was 22.4% , as such 596 patients were discharged alive and followed after discharge with a median of 80 days (IQR 66-91). Total mortality after discharge was 6.4% (n=38) and readmission rate was 11.7% (n=70). Main reasons for readmission were respiratory insufficiency (31%), arterial and venous thrombotic events (16%) or related to a chronic comorbidity (14%). Mortality rates were higher in older patients and patients who experienced delirium during hospital stay. Risk factors for readmission were male sex, discharge to a long-term care facility and COPD.
CONCLUSION: 1 out of 6 COVID-19 positive patients died or was readmitted after discharge. This shows an ongoing vulnerability of COVID-19 patients. Physicians and policy makers should consider this high rate when making decisions on discharge, hospital-capacity planning, and patient monitoring after discharge.

Entities:  

Year:  2020        PMID: 33332036

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  7 in total

1.  Implications for Systemic Approaches to COVID-19: Effect Sizes of Remdesivir, Tocilizumab, Melatonin, Vitamin D3, and Meditation.

Authors:  Ryan D Castle; Michelle A Williams; William C Bushell; J Adam Rindfleisch; Christine Tara Peterson; James Marzolf; Kimberly Brouwer; Paul J Mills
Journal:  J Inflamm Res       Date:  2021-09-22

2.  Predictive modeling for COVID-19 readmission risk using machine learning algorithms.

Authors:  Mostafa Shanbehzadeh; Azita Yazdani; Mohsen Shafiee; Hadi Kazemi-Arpanahi
Journal:  BMC Med Inform Decis Mak       Date:  2022-05-20       Impact factor: 3.298

3.  Hospital readmissions and post-discharge all-cause mortality in COVID-19 recovered patients; A systematic review and meta-analysis.

Authors:  Zhian Salah Ramzi
Journal:  Am J Emerg Med       Date:  2021-11-06       Impact factor: 4.093

4.  Longer length of stay, days between discharge/first readmission, and pulmonary involvement ≥50% increase prevalence of admissions in ICU in unplanned readmissions after COVID-19 hospitalizations.

Authors:  Sarah G Peixoto; Jonas M Wolf; Andressa B Glaeser; Juçara G Maccari; Luiz A Nasi
Journal:  J Med Virol       Date:  2022-05-04       Impact factor: 20.693

5.  Short- and Long-Term Mortality and Mortality Risk Factors among Nursing Home Patients after COVID-19 Infection.

Authors:  Johannes A Booij; Julie C H Q van de Haterd; Sanne N Huttjes; Rogier H P D van Deijck; Raymond T C M Koopmans
Journal:  J Am Med Dir Assoc       Date:  2022-06-20       Impact factor: 7.802

Review 6.  Hospital readmissions and emergency department re-presentation of COVID-19 patients: a systematic review.

Authors:  Sasha Peiris; Joseph L Nates; Joao Toledo; Yeh-Li Ho; Ojino Sosa; Victoria Stanford; Sylvain Aldighieri; Ludovic Reveiz
Journal:  Rev Panam Salud Publica       Date:  2022-10-10

7.  Factors associated with hospital readmissions among patients with COVID-19: A single-center experience.

Authors:  Geneva Guarin; Kevin Bryan Lo; Ruchika Bhargav; Grace Salacup; Ammaar Wattoo; Jean-Gabriel Coignet; Robert DeJoy; Zurab Azmaiparashvili; Gabriel Patarroyo-Aponte; Glenn Eiger; Janani Rangaswami
Journal:  J Med Virol       Date:  2021-06-06       Impact factor: 20.693

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.